These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition. Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649 [TBL] [Abstract][Full Text] [Related]
25. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells. Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995 [TBL] [Abstract][Full Text] [Related]
26. Polymorphisms in the human inhibitory signal-regulatory protein α do not affect binding to its ligand CD47. Hatherley D; Lea SM; Johnson S; Barclay AN J Biol Chem; 2014 Apr; 289(14):10024-8. PubMed ID: 24550402 [TBL] [Abstract][Full Text] [Related]
27. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Matozaki T; Murata Y; Okazawa H; Ohnishi H Trends Cell Biol; 2009 Feb; 19(2):72-80. PubMed ID: 19144521 [TBL] [Abstract][Full Text] [Related]
28. CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPalpha 1. Vernon-Wilson EF; Kee WJ; Willis AC; Barclay AN; Simmons DL; Brown MH Eur J Immunol; 2000 Aug; 30(8):2130-7. PubMed ID: 10940903 [TBL] [Abstract][Full Text] [Related]
29. Structure of signal-regulatory protein alpha: a link to antigen receptor evolution. Hatherley D; Graham SC; Harlos K; Stuart DI; Barclay AN J Biol Chem; 2009 Sep; 284(39):26613-9. PubMed ID: 19628875 [TBL] [Abstract][Full Text] [Related]
30. Soluble extracellular domains of human SIRPα and CD47 expressed in Escherichia coli enhances the phagocytosis of leukemia cells by macrophages in vitro. Lin Y; Yan XQ; Yang F; Yang XW; Jiang X; Zhao XC; Zhu BK; Liu L; Qin HY; Liang YM; Han H Protein Expr Purif; 2012 Sep; 85(1):109-16. PubMed ID: 22813925 [TBL] [Abstract][Full Text] [Related]
31. Signal regulatory protein alpha (SIRPalpha)/CD47 interaction and function. Barclay AN Curr Opin Immunol; 2009 Feb; 21(1):47-52. PubMed ID: 19223164 [TBL] [Abstract][Full Text] [Related]
32. Phylogenetic divergence of CD47 interactions with human signal regulatory protein alpha reveals locus of species specificity. Implications for the binding site. Subramanian S; Boder ET; Discher DE J Biol Chem; 2007 Jan; 282(3):1805-18. PubMed ID: 17098740 [TBL] [Abstract][Full Text] [Related]
33. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Barclay AN; Van den Berg TK Annu Rev Immunol; 2014; 32():25-50. PubMed ID: 24215318 [TBL] [Abstract][Full Text] [Related]
34. Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. Miller TW; Amason JD; Garcin ED; Lamy L; Dranchak PK; Macarthur R; Braisted J; Rubin JS; Burgess TL; Farrell CL; Roberts DD; Inglese J PLoS One; 2019; 14(7):e0218897. PubMed ID: 31276567 [TBL] [Abstract][Full Text] [Related]
35. Blockade of CD47 or SIRPα: a new cancer immunotherapy. Murata Y; Saito Y; Kotani T; Matozaki T Expert Opin Ther Targets; 2020 Oct; 24(10):945-951. PubMed ID: 32799682 [TBL] [Abstract][Full Text] [Related]
36. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology. Burgess TL; Amason JD; Rubin JS; Duveau DY; Lamy L; Roberts DD; Farrell CL; Inglese J; Thomas CJ; Miller TW PLoS One; 2020; 15(4):e0226661. PubMed ID: 32240171 [TBL] [Abstract][Full Text] [Related]
37. The effect of CD47 modified polymer surfaces on inflammatory cell attachment and activation. Stachelek SJ; Finley MJ; Alferiev IS; Wang F; Tsai RK; Eckells EC; Tomczyk N; Connolly JM; Discher DE; Eckmann DM; Levy RJ Biomaterials; 2011 Jul; 32(19):4317-26. PubMed ID: 21429575 [TBL] [Abstract][Full Text] [Related]
38. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Matlung HL; Szilagyi K; Barclay NA; van den Berg TK Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703 [TBL] [Abstract][Full Text] [Related]
39. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis. Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H Front Immunol; 2020; 11():18. PubMed ID: 32082311 [TBL] [Abstract][Full Text] [Related]
40. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis. Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]